DISTILLATION №65 · ALEMBIC LABS

TB-500 — LYS-3 → D-LYS SINGLE SUBSTITUTION (CHIRALITY INVERSION ONLY); LYS-2 RETAINED AS L-LYS TO PRESERVE THE CANONICAL LKKT ACTIN-BINDING MOTIF GEOMETRY

generated 2026-05-04T12:59:07.547363+00:00

PROMISING REGENERATIVE

LYS-3 → D-LYS SINGLE SUBSTITUTION (CHIRALITY INVERSION ONLY); LYS-2 RETAINED AS L-LYS TO PRESERVE THE CANONICAL LKKT ACTIN-BINDING MOTIF GEOMETRY

BETA-ACTIN

AVERAGE CONFIDENCE	PTM / IPTM	VERDICT
82.3%	0.812 / 0.467	PROMISING
TARGET	**UNIPROT**	**BINDING PROBABILITY**
Beta-actin	P60709	—

TLDR

FOLD №65 applies a D-Lys chirality inversion at position 3 of TB-500 (LKKTETQ) to abolish tryptic/plasmin cleavage at the dibasic K2–K3 stretch while preserving the L-Lys-2 actin-binding pharmacophore intact. Despite a strong biochemical hypothesis grounded in serine protease stereospecificity, the structural prediction was DISCARDED due to a critically low ipTM of 0.47 — insufficient confidence in the predicted protein–peptide complex interface geometry. This is a tool-limit failure, not a biological invalidation: AlphaFold-class models are poorly calibrated for single-chirality-inverted residues and short heptapeptides at the margin of their resolution range. The hypothesis remains scientifically coherent and warrants wet-lab follow-up.

EXECUTIVE SUMMARY

TB-500 Lys-3→D-Lys fold DISCARDED: ipTM 0.47 and D-amino acid blindness in Boltz-2 prevent any structural verdict. The protease-resistance hypothesis is mechanistically sound — this is a tool failure, not a biological refutation.

DETAILED ANALYSIS

TB-500 (Ac-LKKTETQ) is the synthetic heptapeptide corresponding to residues 17–23 of thymosin β4, and it functions as the minimal actin-sequestering pharmacophore of the parent protein. Its central mechanism — G-actin engagement via the LKKT N-terminal motif — drives downstream effects on cell migration, wound healing, and angiogenesis that have been extensively validated in preclinical models. The dibasic Lys-2/Lys-3 stretch is simultaneously the functional heart of the molecule and its primary metabolic Achilles heel: Rahaman et al. (2024) demonstrated that serine protease cleavage at or adjacent to K2–K3 generates Ac-LK as the dominant early plasma metabolite, a fragment that is biologically inactive. This metabolic liability is the direct empirical motivation for Fold №65.

The modification hypothesis is elegant in its conservation: rather than altering side-chain length (as was attempted in Fold №16 with Lys-2 → Ornithine, which was DISCARDED because the shorter Orn side chain disrupted actin contact) or introducing a covalent constraint (as in Fold №28's i,i+3 lactam bridge between Lys-3 and Glu-6, which was REFINED), this fold inverts only the stereochemistry of Lys-3 to D-Lys. The side chain length, charge, and ε-amine are fully preserved — the only change is the Cα configuration. Serine proteases including trypsin and plasmin have near-absolute L-stereospecificity at the P1 position; a D-configured residue in the S1 pocket is sterically incompatible with productive catalysis. This is a well-validated principle in therapeutic peptide development, even if it has never been tested specifically in TB-500.

The structural prediction machinery — Boltz-2 used as the primary folding engine — returned a peptide-level pLDDT of 0.82, which is ostensibly reasonable for a heptapeptide. However, the complex-level confidence tells a different story: ipTM of 0.47 places the predicted protein–peptide interface well below the 0.60 threshold conventionally considered necessary to trust the docking geometry. Without a confident interface model, we cannot determine whether the D-Lys-3 Cα inversion repositions the ε-amine in a way that maintains or disrupts salt-bridge contacts with the acidic actin surface. The Boltz-2 affinity module returned no values, and no Chai-1 ensemble was generated for cross-validation. These are the specific tool failures driving the DISCARDED verdict.

A critical compounding factor is that current AlphaFold-class models, including Boltz-2, have no explicit representation of D-amino acid stereochemistry. The model almost certainly treated D-Lys as L-Lys in its energy landscape, meaning the

predicted structure reflects the native L-chirality geometry rather than the actual modified peptide. This is not a minor approximation for a fold where the entire biological hypothesis rests on the stereochemical consequence — the protease resistance and the subtle Cα-Cβ vector shift at position 3 are precisely what cannot be modelled. This is the most fundamental limitation of the current prediction.

In the context of the TB-500 programme at Alembic Labs, this fold occupies a distinct chemical space. Fold №7 (N-terminal acetylation, REFINED, pLDDT 0.87) established the baseline Ac-LKKTETQ/actin prediction. Fold №28 (Lys-3/Glu-6 lactam bridge, REFINED, pLDDT 0.81) showed that Lys-3 can be chemically modified in a way that preserves actin binding — a finding that lends indirect support to the idea that the Lys-3 side chain is not the critical actin contact. Fold №38 (C-terminal palmitoylation, REFINED, pLDDT 0.84) demonstrated that half-life extension strategies at the C-terminus are structurally viable. Fold №51 (Thr-4 → 4F-Phe, DISCARDED, pLDDT 0.83) is the closest precedent — a single non-canonical residue substitution at a central position that also failed on ipTM grounds. The pattern is consistent: heuristic property scores and peptide-level pLDDT are acceptable, but complex interface confidence collapses for non-canonical substitutions in this heptamer.

The literature raises one important counter-hypothesis: Rahaman et al. (2024) identifies Ac-LK as the primary early metabolite, which implies cleavage may also occur after K2 (not exclusively after K3). If cleavage at K2 by a separate protease is contributing meaningfully to metabolism, then D-Lys at position 3 addresses only one of potentially two cleavage events. A comprehensive stability solution might require dual protection — for instance, combining D-Lys-3 with a modified Lys-2 strategy, or combining the D-Lys-3 chirality inversion with the C-terminal palmitoylation from Fold №38 to leverage both protease resistance and albumin-mediated plasma retention simultaneously.

The heuristic peptide profile is worth noting for transparency even under the DISCARDED verdict: aggregation propensity of 0.0 suggests the sequence is unlikely to self-aggregate, and a stability score of 0.6 is moderate. The estimated half-life of 15–45 minutes at the heuristic level reflects the native sequence vulnerability and would theoretically improve under the D-Lys substitution if protease resistance is confirmed experimentally. BBB penetration of 0.067 is expected and not a concern for a peripherally administered regenerative peptide. These are sequence-based heuristic estimates, not wet-lab measurements, and should be interpreted accordingly.

RESEARCH BRIEF

FOLD №65 — TB-500 LYS-3 → D-LYS: CHIRALITY INVERSION FOR PROTEASE RESISTANCE

Verdict: DISCARDED | Class: Regenerative | Target: β-actin (P60709)

TLDR

Fold №65 was **DISCARDED due to a tool-limit failure**: the predicted protein–peptide complex returned an ipTM of **0.47**, below the minimum confidence threshold required to trust the interface geometry. This is not a biological invalidation of the D-Lys-3 hypothesis — it is a failure of current structure prediction infrastructure to model single D-amino acid substitutions in short heptapeptides with sufficient resolution. AlphaFold-class models, including Boltz-2, have no explicit stereochemical representation of D-amino acids; the prediction almost certainly treated D-Lys as L-Lys, rendering the output uninformative for the specific question asked.

WHAT WE TRIED

TB-500 (Ac-LKKTETQ) is the minimal bioactive heptapeptide of thymosin β4, with the LKKT N-terminal motif responsible for G-actin sequestration and downstream regenerative signalling. Its primary metabolic liability is well-documented: Rahaman et al. (2024) established that serine protease cleavage at or adjacent to the dibasic K2–K3 stretch generates Ac-LK as the dominant early plasma metabolite — a biologically inactive two-residue fragment. TB-500's regenerative potential is therefore substantially curtailed by rapid proteolytic degradation.

This fold hypothesized that inverting the stereochemistry of Lys-3 to D-configuration would abolish productive trypsin/plasmin cleavage at the K2–K3 scissile bond, exploiting the near-absolute L-stereospecificity of serine protease S1 pockets at the P1 position. Crucially, the modification preserves full side-chain length and charge at position 3 (D-Lys has the same ε-amine and the same basic character as L-Lys), and leaves Lys-2 in its native L-configuration to maintain the canonical LKKT actin-binding pharmacophore. This directly addresses the lesson from **Fold №16** (Lys-2 → Ornithine, DISCARDED), where shortening the Lys-2 side chain disrupted actin contact — here, no side-chain atoms are removed or altered, only the Cα chirality at position 3 is changed.

WHY IT WAS DISCARDED

The primary discard reason is **insufficient interface confidence**: ipTM = 0.47 at the TB-500/β-actin complex level does not provide actionable structural information about whether the D-Lys-3 modification preserves or disrupts the predicted binding pose. The peptide-level pLDDT of 0.82 is adequate, but this metric reflects intrinsic peptide fold quality, not complex geometry — and for a 7-residue peptide docked against a large globular protein, interface confidence (ipTM) is the decisive metric.

A compounding and arguably more fundamental limitation is that Boltz-2 (and AlphaFold-class models generally) lack explicit D-amino acid stereochemistry in their training data and energy representations. The model almost certainly predicted the structure as if D-Lys were L-Lys, meaning the output does not represent the actual modified peptide at all. The Boltz-2 affinity module returned no values, and no Chai-1 ensemble was generated for cross-validation — removing the two independent checks that would ordinarily allow us to assess agreement. This pattern matches **Fold №51** (Thr-4 → 4F-Phe, DISCARDED, pLDDT 0.83), where non-canonical substitution at a central position also failed to produce a trustworthy interface prediction.

WHAT THIS DOESN'T MEAN

DISCARDED does not mean disproved. The biochemical rationale for D-Lys-3 is mechanistically sound and grounded in well-established serine protease stereochemistry — a principle validated across many therapeutic peptide programmes, even if not yet tested in TB-500 specifically. The prediction infrastructure simply cannot evaluate this specific modification: D-amino acids are invisible to current AlphaFold-class models, and the heptapeptide/actin interface is at the resolution limit for confident complex modelling with a single prediction run. The hypothesis that D-Lys-3 abolishes K2–K3 cleavage while preserving LKKT actin engagement is **scientifically coherent, novel, and experimentally testable** — it has simply not been adjudicated by this fold's tools. The discard reflects a measurement gap, not a negative result.

WHAT WOULD ANSWER THE QUESTION

- **Protease resistance assay (wet lab):** Incubate Ac-LK[D-K]TETQ with human plasma, recombinant trypsin, or plasmin at physiological concentrations; monitor metabolite appearance by LC-MS/MS against the Rahaman et al. (2024) metabolite panel (Ac-LK, Ac-LKK, Ac-LKKTE). Comparison with native Ac-LKKTETQ and the Fold №28 lactam variant would create a systematic stability dataset for TB-500 analogues.

- **G-actin binding assay (SPR or ITC):** Surface plasmon resonance or isothermal titration calorimetry with monomeric G-actin and Ac-LK[D-K]TETQ to directly measure Kd relative to native TB-500. This would resolve the key unknown — whether D-Lys at position 3 is tolerated by the actin binding interface.
- **Molecular dynamics / FEP with D-amino acid-aware force fields:** Classical MD using CHARMM36m or AMBER ff19SB with explicit D-Lys parameters can correctly represent the inverted Cα geometry and sample the actin-binding interface conformation. Free energy perturbation (FEP) would provide a quantitative ΔΔG estimate for L→D chirality at position 3. This is the most appropriate computational approach given that AlphaFold-class tools cannot address this question.
- **Combination with Fold №38 (C-terminal palmitoylation):** If D-Lys-3 is confirmed to block K2–K3 cleavage, combining it with the REFINED C-terminal palmitoylation strategy from Fold №38 (Lys-7/γGlu-Palm) could address both protease-mediated degradation and albumin-mediated half-life extension simultaneously — a dual-mechanism stability analogue worth designing once each component is experimentally validated.

RAW METRICS

Metric	Value	Interpretation
Peptide pLDDT	0.823	Acceptable intrinsic peptide confidence
pTM	0.812	Moderate overall model confidence
ipTM	**0.467**	**Below threshold — interface not reliable**
Chai-1 agreement	None	No cross-model validation available
Boltz-2 affinity	No output	Affinity module did not converge
Aggregation propensity*	0.0	Low (favourable)
Stability score*	0.6	Moderate
Half-life estimate*	~15–45 min	Reflects native sequence; not the D-Lys variant
BBB penetration*	0.067	Not relevant (peripheral peptide therapeutic)

*Heuristic sequence-based estimates only — not wet-lab measurements and not specific to the D-Lys-3 modification.

SEQUENCES

NATIVE

```
LKKTETQ
```

MODIFIED

```
L-K-(D-Lys)-T-E-T-Q
```

CAVEATS

- in silico prediction only — requires wet lab validation
- single-run prediction (not ensembled)
- predicted properties may not reflect real-world biological behavior
- this is research, not medical advice
- AlphaFold-class models (including Boltz-2) have no explicit representation of D-amino acid stereochemistry — the D-Lys-3 modification was almost certainly modelled as L-Lys, making the structural output uninformative for the specific hypothesis tested
- ipTM of 0.47 is below the minimum threshold for reliable interface geometry — complex-level predictions should not be interpreted as meaningful for this fold
- heuristic peptide profile (aggregation, stability, half-life, BBB) is sequence-based and does not account for the chirality inversion at position 3
- literature supports K2–K3 as primary cleavage site but Ac-LK as dominant early metabolite suggests K2 cleavage may also be relevant — D-Lys-3 alone may not fully address metabolic liability
- no Chai-1 ensemble was generated; cross-model agreement cannot be assessed
- Verdict reclassified: DISCARDED → PROMISING. Raw metrics (pLDDT/pTM/ipTM) permit at least the higher tier; the original LLM discard reflected modification chemistry the predictor cannot represent (D-AA, lipid moiety, non-canonical residue). Per the metric-floor rule this is a caveat, not a verdict downgrade. Report text below pre-dates the rule and may still describe the fold as DISCARDED — the structural verdict shown is the authoritative one.

CITATIONS

1. **PMID —** (2024) — — Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro

2. **PMID —** (2012) — — Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry
3. **PMID —** (2012) — — Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
4. **PMID —** (2026) — — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
5. **PMID —** (2026) — — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
6. **PMID —** (2026) — — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
7. **PMID —** (2014) — — Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls

SOLANA SIGNATURE 2n5JA3CcyRes84wMHF173XvskKnR5a7m9236Q8RyZL4wCviWFqaa6QDQhuLRMHHxws9RGoK7cR2cPgWmeSgWfDx8
DATA SHA-256 b7ac02ee0f95d0c0e36dd8382e799e738f66b258d98430f6cd1e0cb14ff68276
VERIFY https://solscan.io/tx/2n5JA3CcyRes84wMHF173XvskKnR5a7m9236Q8RyZL4wCviWFqaa6QDQhuLRMHHxws9RGoK7cR2cPgWmeSgWfDx8